1. Home
  2. TMQ vs ALT Comparison

TMQ vs ALT Comparison

Compare TMQ & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

N/A

Current Price

$2.17

Market Cap

579.8M

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

N/A

Current Price

$2.05

Market Cap

573.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TMQ
ALT
Founded
2004
1997
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
579.8M
573.8M
IPO Year
2012
2005

Fundamental Metrics

Financial Performance
Metric
TMQ
ALT
Price
$2.17
$2.05
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$6.64
★ $17.11
AVG Volume (30 Days)
1.2M
★ 3.4M
Earning Date
10-02-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.37
EPS
★ N/A
N/A
Revenue
N/A
★ $41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 105.00
52 Week Low
$1.94
$1.99
52 Week High
$7.25
$6.44

Technical Indicators

Market Signals
Indicator
TMQ
ALT
Relative Strength Index (RSI) 35.93 33.22
Support Level $1.94 N/A
Resistance Level $2.36 $3.35
Average True Range (ATR) 0.13 0.12
MACD 0.02 0.02
Stochastic Oscillator 53.01 27.27

Price Performance

Historical Comparison
TMQ
ALT

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: